Viatris (VTRS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Viatris

NasdaqGS•Healthcare•Drug Manufacturers - Specialty & Generic

$16.94-0.19(-0.01%)Market open

Market Cap

$19.70B

P/S

1.3x

P/B

1.4x

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

How this company scores

WeakMetricSide Score: 58/100

Grade capped at D — Interest coverage below 1× (0.1x) — earnings cannot cover interest. Strongest: Profitability (17/25); weakest: Balance Sheet & Red Flags (11/25).

Profitability17/25

Growth15/25

Balance Sheet & Red Flags11/25

Cash & Earnings Quality15/25

Strengths

Long cash runwayConsistent free cash flowProfit converts from growthImproving margins

Grade capped at D

Interest coverage below 1× (0.1x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 216.6x5y range 6.0x – 216.6x

Currently above its 8-quarter median.

P/S · 1.3x5y range 0.6x – 1.3x

Currently above its 20-quarter median.

P/B · 1.4x5y range 0.5x – 1.4x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

FCF consistently trails net income (avg -4.6x) — earnings may be inflated by non-cash items or aggressive accounting.

Revenue Decline

Watch

Revenue has softened, declining in 3 quarters. Watch for further erosion.

Price & Volume

Market Cap $19.70B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $14.74B
Q. Revenue: $3.76B
TTM EBITDA: $2.71B
TTM Op. Income: $-87.30M
Q. Op. Income: $6.30M
TTM Net Income: $-410.70M
Q. Net Income: $-118.80M
EPS: $-0.1
Shares Out.: $1.16B

$14.74B in TTM revenue grew 4.4% YoY, reaching $3.76B last quarter. TTM EBITDA of $2.71B and TTM operating income of $-87.30M show growth is flowing through to the bottom line. However, net income is negative at $410.70M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 4 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 38.8%
EBITDA Margin: 15.4%
Op. Margin: 0.2%
Net Margin: -3.2%

Op. margin of 0.2% is down 6.3% YoY — costs are rising relative to revenue. Net margin at -3.2% and gross margin of 38.8% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 1.3x
P/B Ratio: 1.4x

P/S of 1.3x and P/B of 1.4x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $35.04B
Cash: $886.50M
Long-Term Debt: $11.61B
Book Value: $14.26B
D/E Ratio: 0.8
Debt/EBITDA: 20.1

With $35.04B in assets and $11.61B in long-term debt, D/E is 0.8and book value is $14.26B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 2 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $381.80M
TTM Free Cash Flow: $1.95B
FCF Margin: 13.3%
FCF / Net Income: -4.8

TTM FCF of $1.95B on $381.80M in operating cash flow. The FCF / Net Income ratio of -4.8x means the business consumes cash — it is not yet self-funding. Over the past year, free cash flow is up 12% — an improving trend.